What do prescribers think of biosimilars? (Q37977012)

26 August 2017

title

What do prescribers think of biosimilars? (English)

1 reference

26 August 2017

M S Aapro

1

1 reference

26 August 2017

publication date

19 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

7 Suppl 1

1 reference

26 August 2017

page(s)

S51-5

1 reference

Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Determinants of generic drug substitution in Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

The challenge of biosimilars

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Assessing the bioequivalence of biosimilars The Retacrit case

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0193-6

Clinical comparability and European biosimilar regulations

21 January 2018

1 reference

12 December 2020

Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use

1 reference

12 December 2020

Do generics offer significant savings to the UK National Health Service?

1 reference

12 December 2020

The therapeutic equivalence of complex drugs

1 reference

12 December 2020

Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

1 reference

12 December 2020

Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

1 reference

12 December 2020

10.1007/S11523-011-0193-6

Identifiers

DOI

1 reference

26 August 2017

1 reference